SEARCH

SEARCH BY CITATION

References

  • Babiker A., Andersson O., Lund E., Xiu R. J., Deeb S., Reshef A., Leitersdorf E., Diczfalusy U. and Bjorkhem I. (1997) Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J. Biol. Chem. 272, 2625326261.
  • Bjorkhem I. (2006) Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 260, 493508.
  • Bodovitz S. and Klein W. L. (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271, 44364440.
  • Brown J. III, Theisler C., Silberman S. et al. (2004) Differential expression of cholesterol hydroxylases in Alzheimer's disease. J. Biol. Chem. 279, 3467434681.
  • Bu G. (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333344.
  • Canepa E., Borghi R., Vina J., Traverso N., Gambini J., Domenicotti C., Marinari U. M., Poli G., Pronzato M. A. and Ricciarelli R. (2011) Cholesterol and amyloid-beta: evidence for a cross-talk between astrocytes and neuronal cells. J. Alzheimers Dis. 25, 645653.
  • Cordy J. M., Hussain I., Dingwall C., Hooper N. M. and Turner A. J. (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 100, 1173511740.
  • Dasari B., Prasanthi J. R., Marwarha G., Singh B. B. and Ghribi O. (2010) The oxysterol 27-hydroxycholesterol increases beta-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol. 10, 22.
  • Ehehalt R., Keller P., Haass C., Thiele C. and Simons K. (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113123.
  • Famer D., Meaney S., Mousavi M., Nordberg A., Bjorkhem I. and Crisby M. (2007) Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem. Biophys. Res. Commun. 359, 4650.
  • Fassbender K., Simons M., Bergmann C. et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 58565861.
  • Folstein M. F., Folstein S. E. and McHugh P. R. (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 12, 189198.
  • Fukumoto H., Deng A., Irizarry M. C., Fitzgerald M. L. and Rebeck G. W. (2002) Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J. Biol. Chem. 277, 4850848513.
  • Grimm M. O., Grimm H. S., Patzold A. J. et al. (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7, 11181123.
  • Grimm M. O., Rothhaar T. L. and Hartmann T. (2012) The role of APP proteolytic processing in lipid metabolism. Exp. Brain Res. 217, 365375.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Heverin M., Bogdanovic N., Lutjohann D., Bayer T., Pikuleva I., Bretillon L., Diczfalusy U., Winblad B. and Bjorkhem I. (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 45, 186193.
  • Heverin M., Meaney S., Lutjohann D., Diczfalusy U., Wahren J. and Bjorkhem I. (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 46, 10471052.
  • Hixson J. E. and Vernier D. T. (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31, 545548.
  • Jones L., Holmans P. A., Hamshere M. L. et al. (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 5, e13950.
  • Kojro E., Gimpl G., Lammich S., Marz W. and Fahrenholz F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl Acad. Sci. USA 98, 58155820.
  • Kok E., Haikonen S., Luoto T., Huhtala H., Goebeler S., Haapasalo H. and Karhunen P. J. (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 65, 650657.
  • Kolsch H., Heun R., Jessen F., Popp J., Hentschel F., Maier W. and Lutjohann D. (2010) Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim. Biophys. Acta 1801, 945950.
  • Launer L. J., White L. R., Petrovitch H., Ross G. W. and Curb J. D. (2001) Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57, 14471452.
  • Leoni V., Masterman T., Mousavi F. S., Wretlind B., Wahlund L. O., Diczfalusy U., Hillert J. and Bjorkhem I. (2004) Diagnostic use of cerebral and extracerebral oxysterols. Clin. Chem. Lab. Med. 42, 186191.
  • Lewczuk P., Kamrowski-Kruck H., Peters O. et al. (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol. Psychiatry 15, 138145.
  • Lewczuk P., Popp J., Lelental N., Kolsch H., Maier W., Kornhuber J. and Jessen F. (2012) Cerebrospinal Fluid Soluble Amyloid-beta Protein Precursor as a Potential Novel Biomarkers of Alzheimer's Disease. J. Alzheimers Dis. 28, 119125.
  • Lutjohann D. (2006) Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol. Scand. Suppl. 185, 3342.
  • Lutjohann D., Papassotiropoulos A., Bjorkhem I. et al. (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41, 195198.
  • Marwarha G., Dasari B., Prasanthi J. R., Schommer J. and Ghribi O. (2010) Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J. Alzheimers Dis. 19, 10071019.
  • Matsuzaki T., Sasaki K., Hata J., Hirakawa Y., Fujimi K., Ninomiya T., Suzuki S. O., Kanba S., Kiyohara Y. and Iwaki T. (2011) Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study. Neurology 77, 10681075.
  • McKhann G., Drachman D., Folstein M., Katzman R., Price D. and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939944.
  • Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R., Ptok U., Bjorkhem I., von Bergmann K. and Heun R. (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 2732.
  • Pappolla M. A., Bryant-Thomas T. K., Herbert D. et al. (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199205.
  • Popp J., Lewczuk P., Frommann I., Kolsch H., Kornhuber J., Maier W. and Jessen F. (2010) Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEepsilon4 genotype. J. Alzheimers Dis. 22, 459468.
  • Popp J., Lewczuk P., Kolsch H., Giannakopoulos P., Maier W. Kornhuber J., Jessen F. and Lutjohann D. (2011) CNS cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. Alzheimers Dement. 7, 395.
  • Prasanthi J. R., Huls A., Thomasson S., Thompson A., Schommer E. and Ghribi O. (2009) Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 4, 1.
  • Prasanthi J. R., Larson T., Schommer J. and Ghribi O. (2011) Silencing GADD153/CHOP Gene Expression Protects against Alzheimer's Disease-Like Pathology Induced by 27-Hydroxycholesterol in Rabbit Hippocampus. PLoS ONE 6, e26420.
  • Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K. and Pappolla M. A. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321331.
  • Sharma S., Prasanthi R. P. J., Schommer E., Feist G. and Ghribi O. (2008) Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol. Dis. 32, 426432.
  • Shie F. S., Jin L. W., Cook D. G., Leverenz J. B. and LeBoeuf R. C. (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. NeuroReport 13, 455459.
  • Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G. and Simons K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 64606464.
  • Sjogren M., Gustafsson K., Syversen S., Olsson A., Edman A., Davidsson P., Wallin A. and Blennow K. (2003) Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement. Geriatr. Cogn. Disord. 16, 2530.
  • Vanmierlo T., Popp J., Kolsch H. et al. (2011) The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease. Acta Psychiatr. Scand. 124, 184192.
  • Wirths O., Thelen K., Breyhan H., Luzon-Toro B., Hoffmann K. H., Falkai P., Lutjohann D. and Bayer T. A. (2006) Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp. Gerontol. 41, 220224.
  • Xiong H., Callaghan D., Jones A. et al. (2008) Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 29, 422437.